Evidence map›Paper›PMID 37938420›Full record

ArticleRadiological physics and technology2024

Knowledge-based model building for treatment planning for prostate cancer using commercial treatment planning quality assurance software tools.

Nagi Masumoto, Motoharu Sasaki, Yuji Nakaguchi, Takeshi Kamomae, Yuki Kanazawa, Hitoshi Ikushima

Abstract read
PubMed Publisher
In one paragraph

Article in Radiological physics and technology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Nagi MasumotoMedical Research Institute Kitano Hospital, PIIF Tazuke-kofukai, Osaka, Osaka, 530-8480, Japan.
Motoharu SasakiGraduate School of Biomedical Sciences, Tokushima University, 3-18-15 Kuramoto-cho, Tokushima, Tokushima, 770-8503, Japan. msasaki@tokushima-u.ac.jp.ORCID http://orcid.org/0000-0002-9561-0287
Yuji NakaguchiToyo Medic Co., Ltd, Shinjyukuku, Tokyo, 162-0813, Japan.
Takeshi KamomaeDepartment of Radiology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, 466-8550, Japan.
Yuki KanazawaGraduate School of Biomedical Sciences, Tokushima University, 3-18-15 Kuramoto-cho, Tokushima, Tokushima, 770-8503, Japan.
Hitoshi IkushimaGraduate School of Biomedical Sciences, Tokushima University, 3-18-15 Kuramoto-cho, Tokushima, Tokushima, 770-8503, Japan.
Tokushima University · JPKitano Hospital · JPNagoya University · JPToyo Engineering (Japan) · JP

Funding

Promotion Cancer Research 2022 General Proposal B
6 · The paper itself

Abstract

This study devised a method to efficiently launch the RapidPlan model for volumetric-modulated arc therapy for prostate cancer in small- and medium-sized facilities using high-quality treatment plans with the PlanIQ software as a reference. Treatment plans were generated for 30 patients with prostate cancer to construct the RapidPlan model using PlanIQ as a reference. In the context of PlanIQ-referenced treatment planning, treatment plans were developed, such that the feasibility dose-volume histogram of each organ-at-risk fell within F ≤ 0.1. For validation of the RapidPlan model, treatment plans were formulated for 20 patients using both RapidPlan and PlanIQ, and the differences were evaluated. The results of RapidPlan model validity assessment revealed that the RapidPlan-produced treatment plans exhibited higher quality in 11 of 20 patients. No significant differences were found between the treatment plans. In conclusion, high-quality treatment plans formulated using PlanIQ as reference facilitated efficient implementation of RapidPlan modeling.

Indexed as

Prostatic NeoplasmsRadiotherapy, Intensity-ModulatedHumansMaleOrgans at RiskRadiotherapy DosageRadiotherapy Planning, Computer-AssistedSoftwarePlanIQRapidPlanTreatment planning quality

Identifiers

PMID37938420
OpenAlexW4388490182

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.